Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 849 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Prospective Blood Draw Clear all

Conditions: Pleural Effusion
Interventions: Cathflo Activase, Talc Slurry Pleurodesis; Drug
Lead sponsor: Memorial Healthcare System; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Hollywood, Florida

Conditions: Crohn's Disease, Inflammatory Bowel Diseases
Interventions: Fluconazole, Placebo, IL-23 Therapy; Drug · Biological
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Functional Gastrointestinal Disorders, Hypermobile Ehlers-Danlos Syndrome, Postural Orthostatic Tachycardia Syndrome, Autonomic Nervous System Disease, Autonomic Nervous System Imbalance
Interventions: Percutaneous vagal nerve stimulation (pVNS) device, Acoustic vagal nerve stimulation (aVNS) treatment; Device · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 10 Years to 18 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Choledocholithiasis, Cholangiocarcinoma, Benign Stricture of Common Bile Duct
Interventions: Blood culture ( aerobic and anaerobic); Other
Lead sponsor: Texas Tech University Health Sciences Center, El Paso; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: In Vitro Fertilization
Interventions: Observational; Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Adenocarcinoma of the Colon or Rectum
Interventions: FOLFIRI., Atorvastatin; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Angiofibroma of Face, Tuberous Sclerosis
Interventions: Sirolimus 0.2%, Sirolimus 0.4%, Placebo ointment; Drug
Lead sponsor: Aucta Pharmaceuticals, Inc; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 7
States / cities: Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 4 more

Conditions: RENAL INSUFFICIENCY, CHRONIC, LIVER FAILURE, ACUTE, HEART DISEASE
Interventions: ProQuad; Biological
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 6 Months to 24 Months
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Hepatocellular Carcinoma, Hepatitis B, Chronic
Interventions: One time blood draw; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Osteoarthritis
Interventions: Peri-articular injection of marcaine/epinephrine, Peri-articular injection of marcaine alone; Procedure
Lead sponsor: Rush University Medical Center; Other
Eligibility: 19 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Metastatic Breast Cancer, HR+ HER2 Breast Cancer, Metastatic Triple Negative Breast Cancers, Metastatic Triple-Negative Breast Carcinoma
Interventions: Specimen collection, Non-Investigational Antibody-Drug Conjugates (ADC), Medical Record Review; Procedure · Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: San Francisco, California • The Bronx, New York • Durham, North Carolina

Conditions: Hypoxia
Interventions: Vasoconstrictor Agents, Head/neck repositioning, Increase ETCO2, IV fluid bolus, Additional anesthesia, RBC transfusion, Increase FiO2; Drug · Other · Biological
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 65 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Primary Immune Deficiency Diseases (PIDD)
Interventions: 10% IGIV; Biological
Lead sponsor: Evolve Biologics; Industry
Eligibility: 2 Years to 70 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 11
States / cities: Los Angeles, California • Centennial, Colorado • Tampa, Florida + 7 more

Conditions: Colorectal Cancer Stage IV, Colorectal Cancer Metastatic, Colorectal Cancer, Genetics of, Appendix Cancer
Interventions: prospective single arm biomarker (plasma cell-free DNA hydroxymethylation) study; Diagnostic Test
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Neoplasm
Interventions: ExoPred; Diagnostic Test
Lead sponsor: EXoPERT; Industry
Eligibility: 40 Years and older · Female only
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Craniopharyngioma, Child
Interventions: Tumor and Blood Specimens; Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 30 Days to 21 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Aortic Valve Disease, Mitral Valve Disease
Interventions: Cardioplegia Solution, Microplegic Solution No. 1; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Atrial Fibrillation, Stroke, Embolism
Interventions: Rivaroxaban, Warfarin, Matching placebo for Rivaroxaban arm (Warfarin placebo), Matching placebo for Warfarin arm (Rivaroxaban placebo); Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 14,269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 295
States / cities: Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 292 more

Conditions: Glioblastoma Multiforme
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Liver Transplant Infection, Fungal Infection
Interventions: Rezafungin, Standard of care antifungal prophylaxis; Drug
Lead sponsor: Fernanda P Silveira, MD, MS; Other
Eligibility: 18 Years and older
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Breast Adenocarcinoma, Inflammatory Breast Carcinoma
Interventions: pertuzumab, trastuzumab, paclitaxel albumin-stabilized nanoparticle formulation, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 19 Years and older · Female only
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 3
States / cities: Duarte, California • Lancaster, California • South Pasadena, California

Conditions: Hepatocellular Carcinoma, Secondary Malignant Neoplasm of Liver
Interventions: Yttrium-90; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 22 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetes Mellitus, Type 2, Hypoglycemia
Interventions: d-Nav, Blood Glucose Monitoring System; Device
Lead sponsor: Hygieia Research LLC; Other
Eligibility: 21 Years to 70 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Intracranial Hypertension
Interventions: HS-1000 recording; Device
Lead sponsor: HeadSense Medical; Industry
Eligibility: Up to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Akron, Ohio

Search by objective public record fields.

Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis

Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease

Auricular Vagal Nerve Stimulation for Hypermobile Ehlers-Danlos Syndrome

Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD

Immune Modulators and IVF

Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI

Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex

Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant

Biologic Basis of Liver Cancer From Chronic Hepatitis B

Study Comparing Peri-articular Injection of Bupivacaine With and Without Epinephrine

Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

Cerebral Oximetry in Single Lung Ventilation Thoracic Surgery

Study of PlasmaCap IG in Adults and Children With PIDD

Plasma 5hmC Signatures as a Marker of Colorectal / Appendiceal Peritoneal Metastasis

A Prospective Study to Develop and Clinically Validate an in Vitro Diagnostic Medical Device That Uses Blood to Classify Patients at High Risk for Breast Cancer

Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy

Effects of Microplegia on Transfusion Rates After Cardiac Surgery

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

Rezafungin Prophylaxis in Liver Transplant

Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer

Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The Immune System

Multi-Center Study Comparing Efficacy and Safety of Frequently Modified Insulin Therapy

Non-invasive Intracranial Pressure (ICP) Monitoring in Pediatric Patients